Keenan J Mintz1, Guillaume Mercado2, Yiqun Zhou1, Yiwen Ji1, Sajini D Hettiarachchi1, Piumi Y Liyanage1, Raja R Pandey3, Charles C Chusuei3, Julia Dallman4, Roger M Leblanc5. 1. Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA. 2. CESI Engineering School-Angoulême, 16400 La Couronne, France. 3. Department of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37132, USA. 4. Department of Biology, University of Miami, Coral Gables, FL 33146, USA. 5. Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA. Electronic address: rml@miami.edu.
Abstract
Drug traversal across the blood-brain barrier has come under increasing scrutiny recently, particularly concerning the treatment of sicknesses, such as brain cancer and Alzheimer's disease. Most therapies and medicines are limited due to their inability to cross this barrier, reducing treatment options for maladies affecting the brain. Carbon dots show promise as drug carriers, but they experience the same limitations regarding crossing the blood-brain barrier as many small molecules do. If carbon dots can be prepared from a precursor that can cross the blood-brain barrier, there is a chance that the remaining original precursor molecule can attach to the carbon dot surface and lead the system into the brain. Herein, tryptophan carbon dots were synthesized with the strategy of using tryptophan as an amino acid for crossing the blood-brain barrier via LAT1 transporter-mediated endocytosis. Two types of carbon dots were synthesized using tryptophan and two different nitrogen dopants: urea and 1,2-ethylenediamine. Carbon dots made using these precursors show excitation wavelength-dependent emission, low toxicity, and have been observed inside the central nervous system of zebrafish (Danio rerio). The proposed mechanism for these carbon dots abilities to cross the blood-brain barrier concerns residual tryptophan molecules which attach to the carbon dots surface, enabling them to be recognized by the LAT1 transporter. The role of carbon dots for transport open promising avenues for drug delivery and imaging in the brain.
Drug traversal across the blood-brain barrier has come under increasing scrutiny recently, particularly concerning the treatment of sicknesses, such as brain cancer and n class="Disease">Alzheimer's disease. Most therapies and medicines are limited due to their inability to cross this barrier, reducing treatment options for maladies affecting the brain. Carbon dots show promise as drug carriers, but they experience the same limitations regarding crossing the blood-brain barrier as many small molecules do. If carbon dots can be prepared from a precursor that can cross the blood-brain barrier, there is a chance that the remaining original precursor molecule can attach to the carbon dot surface and lead the system into the brain. Herein, tryptophancarbon dots were synthesized with the strategy of using tryptophan as an amino acid for crossing the blood-brain barrier via LAT1 transporter-mediated endocytosis. Two types of carbon dots were synthesized using tryptophan and two different nitrogen dopants: urea and 1,2-ethylenediamine. Carbon dots made using these precursors show excitation wavelength-dependent emission, low toxicity, and have been observed inside the central nervous system of zebrafish (Danio rerio). The proposed mechanism for these carbon dots abilities to cross the blood-brain barrier concerns residual tryptophan molecules which attach to the carbon dots surface, enabling them to be recognized by the LAT1 transporter. The role of carbon dots for transport open promising avenues for drug delivery and imaging in the brain.
Authors: James F Padbury; Sri K Diah; Bethany McGonnigal; Carla Miller; Celine Fugere; Magdalena Kuzniar; Nancy L Thompson Journal: Biochem Biophys Res Commun Date: 2004-05-28 Impact factor: 3.575
Authors: Lei Shi; Jian Hai Yang; Hai Bo Zeng; Yong Mei Chen; Sheng Chun Yang; Chao Wu; Hao Zeng; Osada Yoshihito; Qiqing Zhang Journal: Nanoscale Date: 2016-07-18 Impact factor: 7.790
Authors: Yiqun Zhou; Nabin Kandel; Mattia Bartoli; Leonardo F Serafim; Ahmed E ElMetwally; Sophia M Falkenberg; Xavier E Paredes; Christopher J Nelson; Nathan Smith; Elisa Padovano; Wei Zhang; Keenan J Mintz; Braulio C L B Ferreira; Emel Kirbas Cilingir; Jiuyan Chen; Sujit K Shah; Rajeev Prabhakar; Alberto Tagliaferro; Chunyu Wang; Roger M Leblanc Journal: Carbon N Y Date: 2022-03-10 Impact factor: 11.307
Authors: Eduardo A Veliz; Anastasiia Kaplina; Sajini D Hettiarachchi; Athina L Yoham; Carolina Matta; Sabrin Safar; Meghana Sankaran; Esther L Abadi; Emel Kirbas Cilingir; Frederic A Vallejo; Winston M Walters; Steven Vanni; Roger M Leblanc; Regina M Graham Journal: Pharmaceutics Date: 2022-07-14 Impact factor: 6.525